🇺🇸 FDA
Patent

US 9000173

Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

granted A61KA61K31/444A61K31/4709

Quick answer

US patent 9000173 (Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity) held by Theravance Respiratory Company, LLC expires Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Respiratory Company, LLC
Grant date
Tue Apr 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/444, A61K31/4709, A61K31/56, A61K45/06